|
FAM160A2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.48620013465484E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.77339999854576E-08 |
| Normal-vs-Stage2 |
1.97760000042457E-07 |
| Normal-vs-Stage3 |
2.37170283412524E-11 |
| Normal-vs-Stage4 |
2.85369999963869E-07 |
| Stage1-vs-Stage2 |
1.076160E-01 |
| Stage1-vs-Stage3 |
1.122420E-02 |
| Stage1-vs-Stage4 |
1.417640E-01 |
| Stage2-vs-Stage3 |
8.247200E-01 |
| Stage2-vs-Stage4 |
8.910400E-01 |
| Stage3-vs-Stage4 |
6.940000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.80520043358001E-10 |
| Normal-vs-AfricanAmerican |
4.499400E-03 |
| Normal-vs-Asian |
4.827400E-04 |
| Caucasian-vs-AfricanAmerican |
3.139600E-01 |
| Caucasian-vs-Asian |
1.657640E-01 |
| AfricanAmerican-vs-Asian |
9.782400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.91019996989661E-09 |
| Normal-vs-Female |
1.60970015095074E-10 |
| Male-vs-Female |
5.552000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.22240000000051E-06 |
| Normal-vs-Age(41-60Yrs) |
4.01190000109963E-08 |
| Normal-vs-Age(61-80Yrs) |
1.04179997961751E-11 |
| Normal-vs-Age(81-100Yrs) |
2.044900E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.297800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.062660E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.258600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.280100E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.792800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.413600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.00839999964231E-07 |
| Classical-VS-Follicular |
3.457700E-02 |
| Classical-VS-Other |
8.654000E-01 |
| Classical-VS-Normal |
1.03470000345496E-08 |
| Tall-VS-Follicular |
3.390500E-02 |
| Tall-VS-Other |
1.291640E-01 |
| Tall-VS-Normal |
5.66613422847695E-12 |
| Follicular-VS-Other |
4.227400E-01 |
| Follicular-VS-Normal |
4.17979999500773E-08 |
| Other-VS-Normal |
7.534300E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.38750011480226E-10 |
| Normal-vs-N1 |
6.229499999999E-05 |
| N0-vs-N1 |
3.861600E-01 |
|
|
